Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Enveric Biosciences News

    0,8816 $ -6,01% -0,0564 $
    In : 0,8277 € | 21:19:26 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3DMHB
    ISIN: US29405E2081
    US-Symbol: ENVB
    Typ: Aktie

    Enveric Biosciences News

    29.02.24 - PR Newswire
    Thinking about buying stock in SoundHound AI, Coinbase Global, Societal CDMO, Enveric Biosciences, or Royalty Management Holding?
    Thinking about buying stock in SoundHound AI, Coinbase Global, Societal CDMO, Enveric Biosciences, or Royalty Management Holding? PR Newswire
    08.06.22 - PR Newswire
    Enveric Biosciences to Participate in Upcoming Conferences in June 2022
    Enveric Biosciences to Participate in Upcoming Conferences in June 2022 PR Newswire
    24.05.22 - PR Newswire
    Enveric Biosciences to Participate in the Microdose Psychedelic Capital Conference on May 26, 2022
    Enveric Biosciences to Participate in the Microdose Psychedelic Capital Conference on May 26, 2022 PR Newswire
    17.05.22 - PR Newswire
    Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022
    Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022 PR Newswire
    11.05.22 - PR Newswire
    Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders
    Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders PR Newswire
    05.05.22 - PR Newswire
    Enveric Biosciences to Host Fireside Chat with Dr. Bob Dagher, Chief Medical Officer, on May 17th at 10:00 a.m. ET
    Enveric Biosciences to Host Fireside Chat with Dr. Bob Dagher, Chief Medical Officer, on May 17th at 10:00 a.m. ET PR Newswire
    03.05.22 - PR Newswire
    Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
    Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock PR Newswire
    06.04.22 - PR Newswire
    Enveric Biosciences to Participate in Upcoming Investor Conferences in April 2022
    Enveric Biosciences to Participate in Upcoming Investor Conferences in April 2022 PR Newswire
    31.03.22 - PR Newswire
    Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update
    Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update PR Newswire
    29.03.22 - PR Newswire
    Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application
    Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application PR Newswire
    15.03.22 - PR Newswire
    Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates
    Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-​Inspired Drug Candidates PR Newswire
    03.03.22 - PR Newswire
    Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022
    Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022 PR Newswire
    01.03.22 - PR Newswire
    Thinking about buying stock in Farmmi, Camber Energy, Kaival Brands Innovations, Enveric Biosciences, or Petroleo Brasileiro?
    Thinking about buying stock in Farmmi, Camber Energy, Kaival Brands Innovations, Enveric Biosciences, or Petroleo Brasileiro? PR Newswire
    01.03.22 - PR Newswire
    Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules
    Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-​Based Molecules Robust Portfolio of Psychedelic-​Inspired Molecules Positions Enveric to Achieve Global ...
    17.02.22 - PR Newswire
    Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress
    Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress PR Newswire
    15.02.22 - PR Newswire
    Enveric Biosciences Announces Closing of $10 Million Public Offering
    Enveric Biosciences Announces Closing of $10 Million Public Offering PR Newswire
    11.02.22 - PR Newswire
    Enveric Biosciences Announces Pricing of $10 Million Public Offering
    Enveric Biosciences Announces Pricing of $10 Million Public Offering PR Newswire
    08.02.22 - PR Newswire
    Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecoxib Conjugate
    Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecoxib Conjugate PR Newswire
    27.01.22 - PR Newswire
    Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022
    Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022 PR Newswire
    18.01.22 - PR Newswire
    Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders
    Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders PR Newswire

    Newssuche

    Videos

    18.04.24
    Technical Trading: Gold mit weiterem Potenzial
    Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »